Skip to main content
Premium Trial:

Request an Annual Quote

Metaphorics, Syrrx Ink Ligand-Docking Partnership

NEW YORK, March 1 - Bioinformatics company Metaphorics has struck a  research collaboration with drug-discovery firm Syrrx designed to improve computational tools for docking ligand molecule structures into protein binding sites.

The companies said on Thursday that the collaboration seeks to create new software that might help scientists better predict "the potential complementarity" between ligands and proteins.

Metaphorics, of Mission Viejo, Calif., will bring its DockIt distance-geometry-based technology to the table. This technology was designed to automate high-throughput docking of small molecules versus macromolecular targets.

 

In exchange, Syrrx, which has used DockIt in its own research for one year, will provide its experience in compiling and analyzing structural-proteomics data. Syrrx, based in San Diego, said its DockIt software runs on a Linux cluster of nearly 500 nodes, which it said will increase to 1,000 nodes by mid-year.

According to a statement, Metaphorics and Syrrx believe that "the problem of assessing complementarity between ligands and macromolecular targets is a key area for improvements in existing docking methods."

 

Financial details of the deal were not disclosed.

 

"As one of the leaders in the structural proteomics field, Syrrx is in an excellent position to identify necessary advancements in bioinformatics tools," said Scott Dixon, Metaphorics' Chief Technology Officer. "They have built one of the most advanced technology platforms for the determination of protein structures and this makes them an ideal collaborator for the further development of DockIt."

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.